Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Cancer Biologic Trials

Atlanta, Georgia

Cancer biologic therapy trials in Atlanta, GA

58 cancer biologic therapy studies are recruiting participants at sites in Atlanta as of November 18, 2026, according to ClinicalTrials.gov. Cancer Biologic Trials can help you understand your options and connect with a study team.

Call (888) 343-5902
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Atlanta at a glance

  • 58 studies are recruiting at a site in Atlanta.
  • By phase: Early Phase 1 (1), Phase 1 (10), Phase 1/2 (2), Phase 2 (20), Phase 2/3 (2), Phase 3 (22), Observational (1).
  • By sponsor: university, hospital or other (24), industry (21), government (13).
  • By research area: Lymphoma (23), Lung Cancer (17), Breast Cancer (9), Melanoma (5), Prostate Cancer (3), Pancreatic Cancer (1).
  • Most recent update to one of these records: November 18, 2026.

Breast cancer studies recruiting in Atlanta

Basic details from each study's public record (the 30 most recently updated of 58). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Emory Saint Joseph's Hospital · Emory University Hospital Midtown · Emory University Hospital/Winship Cancer Institute
    Registry record
    NCT06058377 · updated
  2. Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Nammi Therapeutics Inc
    Study site
    Emory University - Winship Cancer Institute
    Registry record
    NCT06582017 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Atlanta, GA on ClinicalTrials.gov.

Lung cancer studies recruiting in Atlanta

  1. Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Emory Saint Joseph's Hospital · Emory University Hospital Midtown · Emory University Hospital/Winship Cancer Institute
    Registry record
    NCT06498635 · updated
  2. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Summit Therapeutics
    Registry record
    NCT06767514 · updated
  3. Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Emory Saint Joseph's Hospital · Emory University Hospital Midtown · Emory University Hospital/Winship Cancer Institute
    Registry record
    NCT06287775 · updated
  4. Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Northside Hospital
    Registry record
    NCT04267848 · updated
  5. A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Piedmont Atlanta Hospital ( Site 0121)
    Registry record
    NCT07554339 · updated
  6. A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study sites
    Emory University School of Medicine-Phase I ( Site 0056) · Northside Hospital ( Site 0055) · Piedmont Atlanta Hospital ( Site 4000)
    Registry record
    NCT06312137 · updated
  7. Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Emory University Hospital Midtown · Emory University Hospital/Winship Cancer Institute
    Registry record
    NCT04181060 · updated
  8. A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Johnson & Johnson Enterprise Innovation Inc.
    Study site
    Emory University Winship Cancer Institute
    Registry record
    NCT06667908 · updated
  9. A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

    • Phase 3
    • All ages
    • All sexes
    Sponsor
    Pierre Fabre Medicament
    Study site
    Arthur M Blank Hospital - Children's Healthcare of Atlanta
    Registry record
    NCT03394365 · updated
  10. Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study sites
    Emory University Hospital Midtown · Emory University Hospital/Winship Cancer Institute
    Registry record
    NCT06116682 · updated
  11. Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study sites
    Emory Saint Joseph's Hospital · Emory University Hospital Midtown · Emory University Hospital/Winship Cancer Institute
    Registry record
    NCT06616584 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Atlanta, GA on ClinicalTrials.gov.

Prostate cancer studies recruiting in Atlanta

  1. Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Emory University Hospital Midtown · Emory University Hospital/Winship Cancer Institute
    Registry record
    NCT03866382 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Atlanta, GA on ClinicalTrials.gov.

Melanoma studies recruiting in Atlanta

  1. A Study to Evaluate OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.

    • Phase 1
    • Ages 18 and older
    • Female participants
    Sponsor
    Outpace Bio, Inc.
    Study site
    Emory - Winship Cancer Institute
    Registry record
    NCT07664735 · updated
  2. SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Immatics US, Inc.
    Study site
    Winship Cancer Institute, Emory University
    Registry record
    NCT06743126 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Atlanta, GA on ClinicalTrials.gov.

Lymphoma studies recruiting in Atlanta

  1. Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Emory Saint Joseph's Hospital · Emory University Hospital/Winship Cancer Institute
    Registry record
    NCT03739814 · updated
  2. Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

    • Phase 2
    • Up to 365 days
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Children's Healthcare of Atlanta - Arthur M Blank Hospital
    Registry record
    NCT06317662 · updated
  3. Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Emory Saint Joseph's Hospital · Emory University Hospital Midtown · Emory University Hospital/Winship Cancer Institute
    Registry record
    NCT06337318 · updated
  4. A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

    • Phase 1
    • Ages 0 to 18
    • All sexes
    Sponsor
    Autolus Limited
    Study site
    Arthur M Blank Hospital
    Registry record
    NCT06173518 · updated
  5. A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • Ages 1 to 30
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Children's Healthcare of Atlanta - Arthur M Blank Hospital
    Registry record
    NCT04546399 · updated
  6. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Children's Healthcare of Atlanta - Arthur M Blank Hospital · Emory Proton Therapy Center · Emory Saint Joseph's Hospital
    Registry record
    NCT05675410 · updated
  7. Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Emory Saint Joseph's Hospital · Emory University Hospital Midtown · Emory University Hospital/Winship Cancer Institute
    Registry record
    NCT07003295 · updated
  8. A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Lyell Immunopharma, Inc.
    Study site
    Northside Hospital
    Registry record
    NCT07188558 · updated
  9. Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

    • Phase 3
    • Ages 18 to 39
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    Emory University Hospital/Winship Cancer Institute
    Registry record
    NCT03150693 · updated
  10. Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

    • Phase 3
    • Ages 60 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    Emory Saint Joseph's Hospital · Emory University Hospital Midtown · Emory University Hospital/Winship Cancer Institute
    Registry record
    NCT05976763 · updated
  11. A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • From 366 days, up to 46 years
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Children's Healthcare of Atlanta - Arthur M Blank Hospital
    Registry record
    NCT06124157 · updated
  12. CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

    • Phase 2
    • Ages 18 to 75
    • All sexes
    Sponsor
    City of Hope Medical Center
    Study site
    Northside Hospital
    Registry record
    NCT06059391 · updated
  13. A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant

    • Phase 1
    • Ages 18 to 75
    • All sexes
    Sponsor
    City of Hope Medical Center
    Study site
    Northside Hospital
    Registry record
    NCT07020533 · updated
  14. Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study sites
    Emory Saint Joseph's Hospital · Emory University Hospital/Winship Cancer Institute
    Registry record
    NCT05633615 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Atlanta, GA on ClinicalTrials.gov.

Ask about studies near Atlanta

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a biologic, such as a vaccine, an antibody, or a cell or gene therapy, as each study is coded in the registry.

Cancer Biologic Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 343-5902

or send a short form

How should we reach you?

Call